Value proposition

Dedicated to giving cancer patients better answers than "maybe"​.

PASSION FOR PRECISION.

ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.

Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer.

ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology.

For more information please visit: www.itm-radiopharma.com.


Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines

Theranostic radioisotope platform technologies, Global network to guarantee security of supply, Strategic alliances in order to further develop Theranostics, and Driving force to establish global standards regarding safety and efficacy of radiopharmaceuticals